APTOCROM Inc. Stock

A109960

KR7109960005

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 2026-07-22			5-day change	1st Jan Change
1,637.00 ^KRW	-2.56%		-3.48%	-67.26%

Jun. 30	Aprogen Biologics Inc. announced that it has received KRW 50.8 billion in funding from APTOCROM Inc.	CI
May. 25	Aprogen Biologics Inc. announced that it expects to receive KRW 50.8 billion in funding from APTOCROM Inc.	CI

Aptocrom Inc, formerly AP Healthcare Inc, is a Korea-based company primarily engaged in the pharmaceutical business. The Company operates its business through three segments. The Pharmaceutical Business segment is mainly engaged in the distribution and sale of drugs such as digestive organs medicine, outer skin medicine, nutrient tonic alteration and antibiotics. The Insulation Business segment is mainly engaged in the production, design, manufacturing and construction of industrial insulation. The Rental Business segment is mainly engaged in the real estate business such as offices and laboratories. The Company sells its products in domestic and overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-07-22	₩1,637.00	-2.56%	27,531
26-07-21	₩1,680.00	-0.88%	4,259
26-07-20	₩1,695.00	-0.24%	3,400
26-07-16	₩1,699.00	+0.18%	3,743
26-07-15	₩1,696.00	-0.29%	4,847

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

Stock Market
Stocks
A109960 Stock

As early as today, start finding the best investment opportunities!

Maximize my profits

Market Cap	18.07B 12.24M 10.72M 9.95M 9.15M 17.23M 1.18B 17.49M 119M 46.41M 578M 45.93M 44.94M 2B	P/E 2024	-2.12x	P/E 2025	-9.5x
Enterprise Value	876M 594K 520K 483K 444K 836K 57.27M 848K 5.75M 2.25M 28.02M 2.23M 2.18M 96.81M	EV / Sales 2024	4.85x	EV / Sales 2025	3.87x
Free-Float	41.27%	Yield 2024 *	-	Yield 2025	-

Jun. 30	Aprogen Biologics Inc. announced that it has received KRW 50.8 billion in funding from APTOCROM Inc.	CI
May. 25	Aprogen Biologics Inc. announced that it expects to receive KRW 50.8 billion in funding from APTOCROM Inc.	CI
May. 14	APTOCROM Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
May. 08	Aprogen Medicines Inc. announced that it has received KRW 12 billion in funding from APTOCROM Inc.	CI
May. 07	APTOCROM Inc. announced that it has received KRW 12.00000164 billion in funding from Nexkonics Inc.	CI
Apr. 27	Aprogen Medicines Inc. announced that it expects to receive KRW 12 billion in funding from APTOCROM Inc.	CI
Apr. 27	APTOCROM Inc. announced that it expects to receive KRW 12.00000164 billion in funding from Nexkonics Inc.	CI
Mar. 20	APTOCROM Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Mar. 15	APTOCROM Inc. announces Annual dividend	CI
Nov. 13	APTOCROM Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-08-13	APTOCROM Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-06-24	AP Healthcare Inc. announced that it has received KRW 10 billion in funding from Aprogen, Inc.	CI
25-05-21	Aprogen Medicines Inc. agreed to acquire an additional 20.06% stake in AP Healthcare Inc. from Aprogen Biologics Inc. for KRW 58.4 billion.	CI

1 day	-2.56%
1 week	-3.48%
Current month	-6.24%
1 month	-8.55%
3 months	-49.79%
6 months	-65.90%
Current year	-67.26%

1 week	1,596	1,697
1 month	1,596	1,790
Current year	1,596	5,400
1 year	1,596	11,820
3 years	1,596	49,900
5 years	1,596	113,000
10 years	1,596	426,000

Manager	Title	Age	Since
Jung-Chool Kim CEO	Chief Executive Officer	70	2022-03-22
Jong-Su Kang SAM	Sales & Marketing	62	-
Young-Suk Yeom AUD	Comptroller/Controller/Auditor	51	-

APTOCROM Inc. Stock

Stocks

A109960

KR7109960005

Pharmaceuticals

Valuation: APTOCROM Inc.

Chart: APTOCROM Inc.

Latest news : APTOCROM Inc.

Quotes and Performance

Course Extremes

Managers and Directors: APTOCROM Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Director	Title	Age	Since
Jae-Seob Kim BRD	Director/Board Member	63	2017-01-09
Jung-Chool Kim BRD	Director/Board Member	70	2022-03-22
Soon-Kyu Park BRD	Director/Board Member	59	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
APTOCROM INC.	-2.56%	-3.48%	-76.68%	-94.79%	12.24M
ELI LILLY AND COMPANY	-1.05%	+0.55%	+49.79%	+151.71%	1,037B
JOHNSON & JOHNSON	+2.00%	+3.49%	+52.22%	+50.20%	615B
ABBVIE INC.	-1.09%	+3.76%	+35.37%	+76.22%	448B
ROCHE HOLDING AG	+2.95%	+2.96%	+30.65%	+24.83%	326B
NOVARTIS AG	-0.61%	+0.83%	+33.46%	+36.87%	293B
ASTRAZENECA PLC	-1.08%	-0.81%	+17.35%	+16.20%	264B
NOVO NORDISK A/S	-1.46%	-6.46%	-29.07%	-42.89%	216B
AMGEN INC.	-0.05%	+2.16%	+19.75%	+55.89%	198B
GILEAD SCIENCES, INC.	+0.05%	-1.03%	+18.31%	+61.63%	162B
Average	-0.26%	+0.66%	+15.12%	+33.59%	355.75B
Weighted average by Cap.	-0.07%	+1.47%	+35.01%	+72.32%

	2024	2025
Net sales	16.4B 11.11M 9.73M 9.03M 8.3M 15.64M 1.07B 15.87M 108M 42.12M 524M 41.69M 40.79M 1.81B	9.81B 6.64M 5.82M 5.4M 4.96M 9.35M 641M 9.49M 64.35M 25.19M 314M 24.93M 24.39M 1.08B
Net income	-28.09B -19.02M -16.67M -15.47M -14.22M -26.8M -1.84B -27.19M -184M -72.15M -898M -71.42M -69.88M -3.1B	-5.56B -3.76M -3.3M -3.06M -2.81M -5.3M -363M -5.38M -36.48M -14.28M -178M -14.13M -13.83M -614M
Net Debt	-25.07B -16.97M -14.87M -13.81M -12.69M -23.91M -1.64B -24.26M -164M -64.38M -801M -63.72M -62.35M -2.77B	-17.19B -11.64M -10.2M -9.47M -8.7M -16.4M -1.12B -16.64M -113M -44.16M -550M -43.7M -42.76M -1.9B